<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37122726</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients.</ArticleTitle><Pagination><StartPage>1107510</StartPage><MedlinePgn>1107510</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1107510</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1107510</ELocationID><Abstract><AbstractText Label="BACKGROUND">The presence of antiphospholipid antibodies (aPLs) plays a pivotal role in the pathogenesis of antiphospholipid antibody syndrome (APS). This study aimed to examine the diagnostic value of a set of non-criteria aPLs and their relevance with APS-related criteria and extra-criteria manifestations.</AbstractText><AbstractText Label="METHODS">From a prospectively constructed database, consecutive APS patients consisting of 114 primary APS (PAPS group), 54 with APS secondary to SLE (SAPS group), 9 seronegative APS (SNAPS), as well as 209 patients with systemic lupus erythematosus (SLE) and 88 healthy controls were included in this study. Levels of criteria aPLs, baseline information, and APS-related criteria and extra-criteria features were extracted from the database. Serum levels of non-criteria aPLs including aPC IgG/IgM, aPI IgG/IgM, aPE IgG/IgM/IgA, aPG IgG/IgM/IgA, anti-phosphatidic acid (aPA) IgG/IgM, aSM IgG/IgM, and aPS/PT IgG/IgM were analyzed with AESKULISA&#xae; ELISA Test Kits.</AbstractText><AbstractText Label="RESULTS">The addition of aPC IgG/M, aPI IgG/M, aPE IgG/M/A, aSM IgG/M, and aPA IgG/M to aCL or a&#x3b2;2GPI IgG/M could significantly increase diagnostic sensitivity and accuracy. A significant difference between PAPS or SAPS and HC was presented in all non-criteria aPLs except for aSM IgM and aPG IgA. Eight out of nine SNAPS patients were positive for at least 1 aPL. Pregnancy morbidity was associated with aSM IgM (r = 0.22) and aSM IgG (r = 0.15). Pre-eclampsia or premature birth was associated with aSM IgG (r = 0.16), aPI IgG (r = 0.22), aPC IgG (r = 0.16), and aPG IgG (r = 0.18). Stroke was associated with aPI IgG (r = 0.2). The clinical association was also observed in DVT with aPS/PT IgG (r = 0.17). Valve lesion was positively associated with aSM IgM (Fisher test p = 0.039), APS nephropathy was associated with aPC IgG (OR 3.797), and livedo reticularis was associated with aPE IgM (OR 15.391).</AbstractText><AbstractText Label="CONCLUSION">Additional detection of non-criteria aPLs including aPC IgG/M, aPE IgG/M/A, aPI IgG/M, aSM IgG/M, and aPA IgG/M could assist in APS diagnosis. The positivity of certain aPLs was statistically associated with both criteria and extra-criteria APS clinical manifestations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Li, Bai, Meng, Wang, Tian, Li, Zeng, Zhao and Hu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Siting</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yina</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Jingjing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xinping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengtao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jiuliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Chaojun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>GNN1DV99GX</RegistryNumber><NameOfSubstance UI="D010396">Penicillamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010396" MajorTopicYN="N">Penicillamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiphospholipid antibody syndrome</Keyword><Keyword MajorTopicYN="N">extra-criteria manifestation</Keyword><Keyword MajorTopicYN="N">non-criteria antiphospholipid antibody</Keyword><Keyword MajorTopicYN="N">pregnancy morbidity</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>3</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37122726</ArticleId><ArticleId IdType="pmc">PMC10132625</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1107510</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thrombosis Haemostasis (2006) 4(2):295&#x2013;306. doi: 10.1111/j.1538-7836.2006.01753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. New Engl J Med (2018) 378(21):2010&#x2013;21. doi: 10.1056/NEJMra1705454</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705454</ArticleId><ArticleId IdType="pubmed">29791828</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheumatic Diseases. (2003) 62(12):1127. doi: 10.1136/ard.2003.006163</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2003.006163</ArticleId><ArticleId IdType="pmc">PMC1754381</ArticleId><ArticleId IdType="pubmed">14644846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradacova P, Slavik L, Ulehlova J, Skoumalova A, Ullrychova J, Prochazkova J, et al. . Current promising biomarkers and methods in the diagnostics of antiphospholipid syndrome: A review. Biomedicines (2021) 9(2):166. doi: 10.3390/biomedicines9020166</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9020166</ArticleId><ArticleId IdType="pmc">PMC7914732</ArticleId><ArticleId IdType="pubmed">33567576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, et al. . 'Non-criteria' aPL tests: Report of a task force and preconference workshop at the 13th international congress on antiphospholipid antibodies, Galveston, TX, USA, April 2010. Lupus. (2011) 20(2):191&#x2013;205. doi:&#xa0;10.1177/0961203310397082</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310397082</ArticleId><ArticleId IdType="pubmed">21303836</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Zheng H, Yin YF, Hu QY, Teng JL, Sun Y, et al. . Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med (2018) 56(4):614&#x2013;24. doi: 10.1515/cclm-2017-0502</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2017-0502</ArticleId><ArticleId IdType="pubmed">29166262</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Gu J, Wan L, Hu Q, Teng J, Liu H, et al. . "Non-criteria" antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther (2020) 22(1):33. doi: 10.1186/s13075-020-2131-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-2131-4</ArticleId><ArticleId IdType="pmc">PMC7035660</ArticleId><ArticleId IdType="pubmed">32085759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Wu Z, Zhang W, Zhang F, Li Y, Liu Y. Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome. Clinica Chimica Acta; Int J Clin Chem (2019) 495:205&#x2013;9. doi: 10.1016/j.cca.2019.04.065</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2019.04.065</ArticleId><ArticleId IdType="pubmed">31002781</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatol (1997) 40(9):1725. doi: 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, et al. . Antiphospholipid syndrome. Nat Rev Dis Primers (2018) 4:17103. doi: 10.1038/nrdp.2017.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.103</ArticleId><ArticleId IdType="pubmed">29321641</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis R, Gonzalez EB, Brasier AR. The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome. Curr Rheumatol Rep (2015) 17(3):16. doi: 10.1007/s11926-014-0485-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-014-0485-9</ArticleId><ArticleId IdType="pubmed">25761923</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre JA, Wagenknecht DR, Faulk WP. Antiphospholipid antibodies: discovery, definitions, detection and disease. Prog Lipid Res (2003) 42(3):176&#x2013;237. doi: 10.1016/S0163-7827(02)00048-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0163-7827(02)00048-6</ArticleId><ArticleId IdType="pubmed">12689618</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkov I, Seguro L, Leon EP, Kov&#xe1;cs L, Roggenbuck D, Schierack P, et al. . Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto- Immun highlights. (2020) 11(1):8. doi: 10.1186/s13317-020-00131-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13317-020-00131-3</ArticleId><ArticleId IdType="pmc">PMC7229627</ArticleId><ArticleId IdType="pubmed">32467748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C, Li S, Xie Z, You H, Jiang H, Shi Y, et al. . Evaluation of the diagnostic value of non-criteria antibodies for antiphospholipid syndrome patients in a Chinese cohort. Front Immunol (2021) 12:741369. doi: 10.3389/fimmu.2021.741369</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.741369</ArticleId><ArticleId IdType="pmc">PMC8461188</ArticleId><ArticleId IdType="pubmed">34567005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, Shums Z, Ateka-Barrutia O, Sorice M, et al. . Closing the serological gap in the antiphospholipid syndrome: The value of "Non-criteria" antiphospholipid antibodies. J Rheumatol (2017) 44(11):1597&#x2013;602. doi: 10.3899/jrheum.170044</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.170044</ArticleId><ArticleId IdType="pubmed">28864642</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol (2018) 9:2971. doi: 10.3389/fimmu.2018.02971</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02971</ArticleId><ArticleId IdType="pmc">PMC6302212</ArticleId><ArticleId IdType="pubmed">30619328</ArticleId></ArticleIdList></Reference><Reference><Citation>Truglia S, Capozzi A, Mancuso S, Recalchi S, Spinelli FR, Perricone C, et al. . A monocentric cohort of obstetric seronegative anti-phospholipid syndrome. Front Immunol (2018) 9:1678. doi: 10.3389/fimmu.2018.01678</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01678</ArticleId><ArticleId IdType="pmc">PMC6062588</ArticleId><ArticleId IdType="pubmed">30079071</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanon A, Pierre G, Willis R, Harris EN, Papalardo E, Romay-Penabad Z, et al. . Performance evaluation and clinical associations of immunoassays that detect antibodies to negatively charged phospholipids other than cardiolipin. Am J Clin Pathology. (2018) 149(5):401&#x2013;11. doi: 10.1093/ajcp/aqy003</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqy003</ArticleId><ArticleId IdType="pmc">PMC5889035</ArticleId><ArticleId IdType="pubmed">29547897</ArticleId></ArticleIdList></Reference><Reference><Citation>Korematsu S, Yamada H, Miyahara H, Ihara K. Increased levels of anti-phosphatidylcholine and anti-phosphatidylethanolamine antibodies in pediatric patients with cerebral infarction. Brain Dev (2017) 39(6):542&#x2013;6. doi: 10.1016/j.braindev.2017.01.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.braindev.2017.01.010</ArticleId><ArticleId IdType="pubmed">28238458</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D. Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. Haematologica (2020) 105(3):562&#x2013;72. doi: 10.3324/haematol.2019.221945</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2019.221945</ArticleId><ArticleId IdType="pmc">PMC7049333</ArticleId><ArticleId IdType="pubmed">32001534</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;don AF, Catano J, Ricard L, Laurent C, de Moreuil C, Urbanski G, et al. . Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study. Arthritis Res Ther (2022) 24(1):33. doi:&#xa0;10.1186/s13075-022-02726-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02726-9</ArticleId><ArticleId IdType="pmc">PMC8788111</ArticleId><ArticleId IdType="pubmed">35078523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciarelli S, Cervera R, Espinosa G, G&#xf3;mez-Puerta JA, Ramos-Casals M, Font J. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev (2006) 6(2):72&#x2013;5. doi:&#xa0;10.1016/j.autrev.2006.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2006.06.007</ArticleId><ArticleId IdType="pubmed">17138246</ArticleId></ArticleIdList></Reference><Reference><Citation>Artim-Esen B, Diz-K&#xfc;&#xe7;&#xfc;kkaya R, &#x130;nan&#xe7; M. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep (2015) 17(3):14. doi:&#xa0;10.1007/s11926-014-0494-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-014-0494-8</ArticleId><ArticleId IdType="pubmed">25740703</ArticleId></ArticleIdList></Reference><Reference><Citation>Ames PRJ, Merashli M, Bucci T, Pastori D, Pignatelli P, Arcaro A, et al. . Antiphospholipid antibodies and autoimmune haemolytic anaemia: A systematic review and meta-analysis. Int J Mol Sci (2020) 21(11):4120. doi:&#xa0;10.3390/ijms21114120</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21114120</ArticleId><ArticleId IdType="pmc">PMC7313475</ArticleId><ArticleId IdType="pubmed">32527000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontic M, Stojanovich L, Mijailovi&#x107;-Ivkovi&#x107; M, Velinovi&#x107; M, Srnka J, Zdravkovic M. Are the cutaneous manifestations in patients with primary antiphospholipid syndrome a marker for predicting lung manifestations? Clin Exp Rheumatol (2018) 36(1):56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">28770705</ArticleId></ArticleIdList></Reference><Reference><Citation>Franc&#xe8;s C, Niang S, Laffitte E, Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: Two hundred consecutive cases. Arthritis Rheumatol (2005) 52(6):1785&#x2013;93. doi: 10.1002/art.21041</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21041</ArticleId><ArticleId IdType="pubmed">15934071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikas P, Chalikias G, Tziakas D. Cardiovascular implications of sphingomyelin presence in biological membranes. Eur Cardiol (2018) 13(1):42&#x2013;5. doi: 10.15420/ecr.2017:20:3</Citation><ArticleIdList><ArticleId IdType="doi">10.15420/ecr.2017:20:3</ArticleId><ArticleId IdType="pmc">PMC6159463</ArticleId><ArticleId IdType="pubmed">30310470</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>